European Journal of Clinical Pharmacology

, Volume 33, Issue 6, pp 625–628 | Cite as

Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects

  • R. A. Morrison
  • S. M. Singhvi
  • W. A. Creasey
  • D. A. Willard


To support the increasing use of intravenous β-blockers during cardiovascular emergency and surgery, dose proportionality of pharmacokinetics of nadolol was evaluated after intravenous administration of 14C-nadolol at doses of 1, 2 and 4 mg to nine healthy volunteers. There were no observed differences in the excretion or the pharmacokinetics of nadolol with respect to the dose administered. Over a 72-h period after drug administration, an average of about 60% of the dose was excreted in the urine and about 15% was excreted in the feces. The range of values for total body clearance (219 to 250 ml·min−1), renal clearance (131 to 150 ml·min−1), mean residence time (10.5 to 11.3 h), half-life (8.8 to 9.4 h), and steady-state volume of distribution (Vss) (147 to 157 l) indicated that nadolol was extensively distributed and slowly cleared from the body. There was a linear correlation (r2=0.97) between the area under the plasma concentration of nadolol versus time curve (AUC) and the dose. All pharmacokinetics parameters, except Vss, were slightly, but significantly, different at the 4 mg dose. Superposition of the dose-normalized average concentrations indicated that despite these minor differences in parameters, the pharmacokinetic behavior of nadolol was linear with respect to dose. Urinary excretion of nadolol was dose independent.

Key words

nadolol pharmacokinetics 14C-nadolol healthy volunteers i.v. administration 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Matangi MF, Neutze JM, Graham KJ, Hill DG, Kerr AR, Barratt-Boyes BG (1985) Arrhythmia prophylaxis after aorta-coronary bypass — the effect of minidose propranolol. J Thorac Cardiovasc Surg 89: 439–443Google Scholar
  2. 2.
    Hollenberg NK, Adams DF, McKinstry DN, Williams GH, Boruck LJ, Sullivan JM (1979) Beta-adrenoceptor-blocking agents and the kidneys: Effect of nadolol and propranolol on the renal circulation. Br J Clin Pharmacol 7 [Suppl 2]: 219S-225SGoogle Scholar
  3. 3.
    Textor SC, Fouad FM, Tarazi RC, Vidt DG, Gifford RW (1972) Redistribution of cardiac output to the kidneys during nadolol administration. N Engl J Med 307: 601–605Google Scholar
  4. 4.
    Dupont AG, Vanderneipen P, Bossuyt AM, Jonckheen MH, Six RO (1985) Nadolol in essential hypertension: Effect on ambulatory blood pressure, renal hemodynamics and cardiac function. Br J Clin Pharmacol 20: 93–99Google Scholar
  5. 5.
    Yeh KC, Kwan KC (1978) A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximations. J Pharmacokinet Biopharm 6: 79–98Google Scholar
  6. 6.
    Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New York, NYGoogle Scholar
  7. 7.
    Dreyfuss J, Brannick LJ, Vukovich RA, Shaw JM, Williard DA (1977) Metabolic studies in patients with nadolol: Oral and intravenous administration. J Clin Pharmacol 17: 300–307Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • R. A. Morrison
    • 1
  • S. M. Singhvi
    • 1
  • W. A. Creasey
    • 1
  • D. A. Willard
    • 2
  1. 1.The Squibb Institute for Medical ResearchPrincetonUSA
  2. 2.The Medical Center at PrincetonPrincetonUSA

Personalised recommendations